Rates, risks and routes to reduce vascular dementia (R4vad), a UK-wide multicentre prospective observational cohort study of cognition after stroke: Protocol by Wardlaw, Joanna M. et al.
 
 
 
 
 
Wardlaw, J. M. et al. (2020) Rates, risks and routes to reduce vascular 
dementia (R4vad), a UK-wide multicentre prospective observational cohort 
study of cognition after stroke: Protocol. European Stroke Journal, (doi: 
10.1177/2396987320953312). 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/224183/    
                    
 
 
 
 
 
 
Deposited on: 19 October 2020 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
ESO-20-0107 Revision 1 
1 
 
Title: Rates, Risks and Routes to Reduce Vascular Dementia (R4VaD), a UK wide multicentre 
prospective observational cohort study of cognition after stroke: Protocol. 
 
Authors: JM Wardlaw MD, FRCR, FMedSci1, F Doubal, MBChB, PhD, FRCP1, R Brown PhD1, E 
Backhouse PhD1, L Woodhouse MSc2, P Bath, PhD, DSc, FMedSci2, T Quinn MBChB, MD3, T 
Robinson MBChB, DM, FRCP 4, HS Markus, DM, FRCP5, R McManus MBBSc, PhD, FRCGP6, DJ 
Werring FRCP PhD FESO 7, JT O’Brien BM BCh, DM, FRCPsych5, N Sprigg DM, FRCP 2, A Parry-
Jones PhD MRCP 8, RM Touyz MBBCh, PhD3, S Williams, PhD, FMedSci9, YH Mah MBBChir PhD 
9, H Emslie PhD FRCP 10 and the R4VaD Investigators*  
 
Affiliations:  
1 JW, FD, RB, EB, Centre for Clinical Brain Sciences and UK DRI at the UoE, Edinburgh, UK;  
2 PB, NS, LW- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, 
Nottingham UK;  
3 TQ, RMT, Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK 
4TR, Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, 
University of Leicester.  
5 HSM, Dept of Neurology, JTO’B -Department of Psychiatry, University of Cambridge, 
Cambridge, UK 
6RMcM, Dept of General Practice, University of Oxford, UK 
7DJW, National Hospital for Neurology and Neurosurgery, Queen Square 
University College Hospitals NHS Foundation Trust and Stroke Research Centre 
Institute of Neurology, University College, London.  
8 AP-J Division of Cardiovascular Sciences, School of Medicine, Faculty of Biology, Medicine & 
Health, The University of Manchester, Manchester Academic Health Science Centre, Oxford 
Road, Manchester, M13 9PL, UK 
9SW, YHM, King's College Hospital NHS Foundation Trust, and School of Biomedical 
Engineering and Imaging Sciences, King's College London, UK  
10 HE – Department of Neurology, Lancashire Teaching Hospitals NHS Foundation Trust & 
Lancaster Medical School, Lancaster University 
 
Corresponding Author: Prof JM Wardlaw, Centre for Clinical Brain Sciences, Chancellor’s 
Building, University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK. 
Email: Joanna.wardlaw@ed.ac.uk 
* R4VaD Investigators see Appendix 
 
 
 
 
 
 
ESO-20-0107 Revision 1 
2 
 
Abstract 
Background: Stroke commonly affects cognition and, by definition, much vascular dementia 
follows stroke. However, there are fundamental limitations in our understanding of vascular 
cognitive impairment, restricting understanding of prevalence, trajectories, mechanisms, 
prevention, treatment, and patient service needs.  
Aims: Rates, Risks and Routes to Reduce Vascular Dementia (R4VaD) is an observational 
cohort study of post-stroke cognition. We aim to recruit a wide range of patients with stroke, 
presenting to geographically diverse UK hospitals, into a longitudinal study to determine rates 
of, and risk factors for, cognitive and related impairments after stroke, to assess potential 
mechanisms and improve prediction models. 
Methods: We will recruit at least 2000 patients within six weeks of stroke with or without 
capacity to consent, and collect baseline demographic, clinical, socioeconomic, lifestyle, 
cognitive, neuropsychiatric and informant data using streamlined patient centred methods 
appropriate to the stage after stroke. We will obtain more detailed assessments at 4-8 weeks 
after the baseline assessment and follow-up by phone and post yearly to at least 2 years. We 
will assess diagnostic neuroimaging in all, and high-sensitivity inflammatory markers, 
genetics, blood pressure (BP) and diffusion tensor imaging in mechanistic sub-studies. 
Planned Outputs: R4VaD will provide reliable data on long-term cognitive function after 
stroke, stratified by prior cognition, stroke- and patient-related variables, and improved risk 
prediction. It will create a platform enabling sharing of data, imaging and samples. 
Participants will be consented for re-contact, facilitating future clinical trials, and providing a 
resource for the stroke and dementia research communities. 
 
Study registration: ISRCTN18274006 
 
Key words: stroke, cognition, dementia, observational 
 
Word count: abstract 245; text 4324; references 54; tables 4; figs 2 
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Introduction and rationale  
 
Stroke and dementia share many risk factors1 and each is a risk factor for the other.2, 3 Stroke 
and transient ischaemic attack (TIA) increase the risk of post-stroke cognitive impairment 
(PSCI) and vascular dementia (VaD), but risk-prediction for individuals remains difficult.2, 4 
There are limited data on rates and progression of PSCI by time and clinically-relevant strata, 
that account for pre-morbid and pre-stroke cognition, medical, lifestyle and socioeconomic 
factors,2 but improved understanding of these predictors would improve risk stratification, 
identify mechanisms and intervention targets.1  
 
The limited progress to date in predicting, understanding and ameliorating PSCI reflects the 
variability of stroke presentations, its consequences and co-morbidities. Nonetheless, post 
stroke cognitive impairment is a common, under-researched problem and a priority for 
patients, carers, health services, funders, policy makers and governments in recent years.5 
 
Rates, Risks and Routes to Reduce Vascular Dementia (R4VaD) is a Priority Programme in 
Vascular Dementia funded by the Stroke Association, British Heart Foundation and 
Alzheimer’s Society. It is a large, multicentre, longitudinal, inclusive study in patients 
presenting with stroke or TIA to UK Stroke Centres, using standardised proportionate 
ascertainment methods to assess cognition, functional and neuropsychiatric outcomes up to 
at least two years after stroke.    
 
 
Methods & Design  
 
Study aims and objectives 
The primary aim of R4VaD is to determine rates of cognitive impairment and dementia up to 
at least two years after stroke across a wide range of stroke severities and participant 
demographics including socioeconomic status and premorbid cognitive status.  
Our secondary aims are to:  
1. Identify key risk predictors and improve risk prediction model precision for individuals; 
2. Improve understanding of mechanisms of PSCI; 
3. Improve cognitive testing for PSCI; 
4. Provide data to inform the design of future RCTs and help plan clinical services for 
patients with PSCI;  
5. Establish a well phenotyped population, in follow-up, with consent for re-contact for 
future studies and trials. 
 
The objectives are to: 
1. Recruit a large (>2000) sample of patients post stroke/TIA and perform baseline then 
regular comprehensive follow up assessments to at least 2 years post stroke 
2. Classify cognitive outcomes into subtypes characterised by patient related factors 
3. Construct and refine a comprehensive, flexible, patient-focussed and patient-sensitive test 
battery during the study 
4.  Identify risk stratification scores for patients’ post-stroke cognitive function to inform 
outcome event rates and provide data for sample size calculations for trials 
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5.  Synthesise a registry of participants willing to consider taking part in future studies/trials. 
 
Ethics and Regulatory approvals 
R4VaD is approved by Ethics Committees in Scotland (A Research Ethics Committee; Ref 
number 18/SS/055), England (Health Research Authority), Wales (Health and Care Research) 
and Northern Ireland (all Northeast Newcastle and North Tyneside 1; Ref number 
18/NE/0150). NHS Research and Innovation Office approval is given in each participating site. 
The study is adopted by the National Institute for Health Research (NIHR) Clinical Research 
Network in England, Wales and Northern Ireland and the Stroke Research Network in 
Scotland.   
R4VaD is registered (ISRCTN18274006). 
All participants, or their appropriate guardian, and informants, give written informed consent. 
 
Patients 
Inclusion and exclusion criteria  
We aim to recruit at least 2000 participants from UK stroke centres in all four nations. We will 
include all adult (age 18 or over) patients with ischaemic or intracerebral haemorrhage (ICH) 
or TIA, who are expected to survive to at least 12 weeks after stroke, and whether or not they 
have a diagnosis of cognitive impairment or dementia prior to stroke, with or without capacity 
to consent. We exclude patients with subarachnoid haemorrhage (Table 1).  
 
Table 1: Inclusion and exclusion criteria 
 
Inclusion criteria 
• Patients aged ≥18,  with no upper age  
• Ischaemic, or spontaneous haemorrhagic (non-traumatic, 
non-subarachnoid haemorrhage, non-AVM) stroke and 
transient ischaemic attack (TIA; where feasible*) with no 
severity limit  
• Expected to survive at least to 12 weeks 
Exclusion criteria 
• Inclusion criteria are not met, in particular, at onset, the 
patient is not expected to survive more than 12 weeks 
• Aneurysmal, traumatic or AVM-associated haemorrhage or 
subarachnoid haemorrhage 
• Stroke mimics such as brain tumours 
*Patients with TIA may be recruited where the research resource is sufficient, but patients with stroke remain 
the priority where research resource is restricted. 
 
Participant identification, recruitment and consent 
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Participants are recruited from in- and out-patient stroke services. Informants, usually a close 
family member, are also requested.  
 
Participants with capacity (and informants where available) give informed written consent at 
study entry prior to any study-related procedures.  Patients without capacity have consent, 
assent, opinion, or waiver of consent obtained from the appropriate person within each 
jurisdiction since guardianship for persons without capacity differs in Scotland, Northern 
Ireland, England, and Wales. The appropriate person may also act as the informant. Patients 
who regain capacity and wish to remain in the study, provide written informed consent. 
Where participants lose capacity during the study, we continue to collect data but seek 
consent for this from the appropriate consultee, relative, friend, welfare attorney, as defined 
by jurisdiction. If participants withdraw, we retain data collected to that point and record 
reasons for withdrawal if available. Consent includes the ability to undertake trial procedures 
remotely, ie to use phone or postal contact, if needed due to patient circumstance or national 
policy. 
 
Co-enrolment 
Co-enrolment in R4VaD and other relevant observational studies and Clinical Trials of 
Investigational Medicinal Products (CTIMPs) is encouraged as long as the two studies would 
not confound each other’s results, make attribution of adverse reactions difficult in the CTIMP 
or overburden participants. Specifically, to reduce burden on participants, data consistent 
with R4VaD and the co-enrolled study are shared; similarly results of tests performed clinically 
(eg MoCA) can be used in R4VaD and vice versa to avoid repetition and reduce workload for 
the patient and staff.  
 
Data capture and management 
All data are entered into a secure password-protected electronic case record form (eCRF) 
hosted at the University of Nottingham. Baseline and 4-14 week follow-up data are entered 
by the local researchers at each participating hospital, whereas one and two year follow-up 
data are entered by the central follow-up co-ordinators. All entries are validated, tracked and 
any changes are documented. Each participant’s data are anonymised and participants are 
identified only by their Study ID number. Paper versions of the CRF are available to assist data 
collection which are filed in the patient’s folder and held securely at site. The eCRF includes 
range and validity checks, tracks missing/incomplete data and flags follow-up timepoints to 
aid the flow of data collection, study recruitment tracking and study management.  
 
Study assessments 
Our approach to assessment recognises that different stages after stroke need specific 
approaches.6 We assess:  
1. pre-morbid, i.e. peak adult cognitive ability  
2. pre-stroke cognitive decline  
3. post stroke cognitive status at specific points after stroke to map cognitive 
trajectories 
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4. demographic, clinical (current, past, pre-stroke medications and stroke-specific 
treatments), socioeconomic, lifestyle, neuropsychiatric symptoms including 
fatigue, and functional status at relevant timepoints. 
 
Our approach to assessment was informed by experts in stroke, cognition, neuropsychological 
assessment and lay advisors.6, 7 We drew upon existing knowledge and best practice and 
implemented the following principles over multiple iterations and testings of the assessment 
schema: a) avoid overburdening participants and carers, b) avoid duplication, c) each test is 
essential, d) consistent across stages, e) valid, with wide stroke usage8 for external 
comparison (e.g. we already have data on Telephone Interview for Cognitive Status (TICS) 
(cognition) and Zung (mood) for more than 7500 pts,9) and f) minimise known biases.10, 11    
 
We were guided by Cochrane Dementia, Dementia Platform UK (DPUK) Vascular Experimental 
Medicine Study Group,7 and focus groups with study nurses and clinicians. People living with 
stroke have consistently recognised post stroke cognitive problems as a priority.5 Our 
approach to R4VaD was also informed by our extensive work with stroke survivors and their 
caregivers. The R4VaD Participant Panel and participant groups in study sites commented on 
timing and duration of cognitive assessments, avoiding repetitiveness, care of patients with 
cognitive difficulties, importance of including all stroke severities, suitability of questions 
deemed to be quite personal, carer involvement and careful wording of study information to 
convey the work’s importance while not exacerbating worry in those recently overwhelmed 
by acute stroke. Research practitioners at recruiting sites also identified and shared good 
practice ideas via regular site meetings and electronically  
(https://stroke.nottingham.ac.uk/r4vad/live/r4vad_login.php).  
 
Our data collection focuses on efficiency (minimising test time and duplication), validity 
(systematic reviews of test properties,6, 12 relevance to VCI8 and feasibility (postal or 
telephone versions available13). Since cognitive and neuropsychological batteries may 
become overly burdensome and unsuitable in patients with stroke, we use a ‘stepped 
approach’ with brief assessments covering core domains for all participants, and more 
detailed test versions as feasible.14, 15  Patients with aphasia, hemiparesis or hemianopia are 
encouraged to complete as much of the tests as they are able to; reasons for inability to 
complete tests are recorded. The neuropsychological effects of vascular disease include 
delirium, fatigue, apathy and mood disorders16 in addition to cognition, quality of life and 
well-being, providing comprehensive physical, functional, cognitive and neuropsychiatric 
data.  
 
Our follow-up is flexible and includes face-to-face (although ideal, it is unfeasible in all, or in 
a study of this size), telephone, or postal follow-up; online/email follow-up could be used.  
Combining phone and postal questionnaires allows a greater range of cognitive assessment 
than either alone (e.g. postal allows visuospatial tests), improves rates of data completion 
and reduces losses to follow-up. Failure to complete a test may reflect patient status and is 
thus an outcome in its own right, so we record non-testability, employing “intention to 
diagnose” approaches to deal with test non-completion.14 Finally, informants know the 
patient well, can recognise change,12  and are invaluable if communication problems preclude 
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even brief direct-to-patient assessments. Therefore we provide validated informant versions 
of questionnaires. Engagement with relatives and partners also increases retention and data 
completeness, and provides data on care-giver strain. 
 
Figure 1 summarises the study visits. Supplement Table 1 shows the assessments performed 
at each visit and Table 2 shows the validated tests used to perform these assessments.  
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Table 2: List of validated assessments  
Feature assessed Main test Abbreviation Additional contributing 
tests 
Functional outcome Modified Rankin Scale17 mRS SIS;18  
Barthel;  
Lawton19 
Quality of life EuroQol-5D  EQ-5D ONS-4 
Wellbeing Office for National Statistics Personal Well-being ONS-4  
Basic and extended 
activities of daily living 
Barthel20   Lawton19  
Frailty  Clinical Frailty Scale21   
Cognition:  
multidomain screening 
Montreal Cognitive Assessment,22  
modified Telephone Interview for Cognitive Status23 
MoCA 
TICS-m 
 
Cognition:  
domain specific tests 
Trail Making Test A and B, with timing and error counts;24 
Letter Digit Coding;25 Boston Naming Test;26 verbal fluency for F, S 
and A;27 animal naming26 
Trails A, B 
LDC 
Boston Naming 
Animal naming 
 
 
Cognition:  Informant Questionnaire on Cognitive Decline in the Elderly 28 IQCODE  
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Informant-provided  
Anxiety and depression Zung;29  
Generalised Anxiety Disorder;30  
Patient Health Questionnaire (PHQ);31  
 
Zung 
GAD 
PHQ 
 
EQ-5D; 
Fatigue  Brief Fatigue Inventory;  
 
BFI PHQ  
Zung29 
Apathy  PHQ;  
Informant Neuropsychiatric Inventory Questionnaire Version32 
NPI-Q Zung29  
 
Mobility, dexterity Stroke Impact Scale18  
Barthel 
Lawton 
SIS EQ-5D 
Current Social Support Social Support Scale21  SSS  
Delirium 4 A’s test33 4AT  
Educational exposure Years in full time education; age leaving full time education   
Premorbid cognitive 
ability 
National Adult Reading Test34 NART Educational exposure 
Current SES Current occupation; postcode   
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Childhood SES Father’s and mother’s occupations   
SES = socioeconomic status 
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We assess: functional status, quality of life, well-being, basic and extended activities of daily 
living, mobility, frailty, cognition using multidomain screening tools and domain specific tests, 
anxiety, depression, fatigue, and apathy. Several questionnaires (Table 2) contribute several 
types of information. We record current social support, place of residence, educational 
exposure (to estimate premorbid cognitive ability), current and childhood socioeconomic 
status (SES). We use Informant-provided Informant Questionnaire on Cognitive Decline in the 
Elderly (IQCODE)28 to estimate pre-stroke cognitive decline and 4 A’s test (4AT)  for delirium 
around the time of stroke.  
 
Insert Figure 1 here 
 
Baseline assessment occurs as soon as possible, between 24 hours to 6 weeks after stroke, 
the latter to enable patients to be included who were very ill in the first week but then start 
to recover. We record details of the index stroke including severity (worst and at the time of 
assessment with National Institutes of Health Stroke Scale, NIHSS) and evidence of delirium 
(clinical, from informant using 4AT), past medical and family history, lifestyle (smoking, 
alcohol and dietary salt intake and exercise), pre-stroke medication, treatment for the index 
stroke, visual and auditory impairments. Informants are asked about pre-stroke cognition 
(IQCODE,12). BP is assessed using standard protocols and validated, calibrated monitors to 
obtain three measures at least one minute apart.35 Routine brain imaging (CT in most, MRI in 
some) is collected centrally to classify the index stroke (location, size, subtype, arterial 
territory) and other (prior stroke lesions, white matter lesions, lacunes, atrophy in all; 
perivascular spaces, microbleeds, siderosis where MRI is available) findings using well-
validated standard visual assessment tools.36, 37 Bloods are taken for genetic analysis.  
 
Early follow-up is at 6+/-2weeks post baseline assessment (i.e. 4-14 weeks after stroke) by 
local site staff. At this stage, participants are more likely to be able to complete multidomain 
cognitive tests (Table 3),8 or shorter tests.38 The assessment coincides with local clinic review, 
those remaining in hospital being assessed in hospital. Contact by post or phone is also 
offered. We record place of residence, functional status, or if the patient has died, the cause. 
Every effort is made to overcome barriers to follow-up (e.g. arranging transport if necessary; 
contacting the patient via the Informant, obtaining information from medical case-records 
and the Informant) and obtain reliable data. BP is assessed as at baseline. Bloods are taken 
for inflammatory markers (and genetics where not taken at baseline) and future analyses.  
 
Annual follow-up (to 2 years minimum, maximum 4 years) is performed centrally, by post and 
phone. We avoided online/email follow-up since only 53% of 1-adult and 85% of 2-adult 
households aged>65 have internet (Office of National Statistics 2016).39 Central follow-up by 
validated telephone and post methods occurs at three centres, UCL, Leicester and Glasgow, 
spreading the study activities across core sites.   
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Outcome measures 
 
Primary outcome  
The primary outcome of R4VaD is cognitive decline or (incident and prevalent) 
dementia/major neurocognitive disorder up to at least 2 years post stroke assessed with a 
seven-point ordinal scale that includes death (Table 3). The ordinal scale maps onto the four- 
point DSM-5 criteria for major neuro-cognitive disorder (dementia) diagnosis but provides 
more granularity in the ‘dementia (major neurocognitive disorder)’ category to reflect 
practical implications. The seven-point ordinal scale incorporates cognition (using MoCA and 
TICS-m, so as to apply to all patients) and function (mRS, and Barthel), clinical diagnosis of 
dementia made outside R4VaD, place of residence, and IQCODE. It also incorporates the 
number of affected domains of cognition (which may have practical implications e.g. if some 
domains are more restrictive on independence than others) and impact of the cognitive 
impairments on functional dependency.  
 
This ordinal approach is pragmatic and uses all available data40 (including prescriptions) to 
categorise neurocognitive status while minimising the impact of missing or untestable data. 
Ordinal data facilitate sophisticated quantitative analyses (a comprehensive statistical 
analysis plan will be described in a separate paper). Finally, since this approach could be useful 
for future trials in VCI, R4VaD will assess ordinal classification and analysis approaches at 
scale.   
 
Secondary outcomes include the following (the list is not exhaustive) 
1. Death 
2. Disability (mRS) 
3. Function in activities of daily living (Barthel; Lawton; SIS) 
4. Recurrent stroke or other vascular events 
5. Domains of cognition (complex attention, executive, language, memory and visuospatial 
function), allowing for analysis at the individual domain level or at participant level 
creating normalised, aggregate ‘z scores’ 
6. Other neuropsychological outcomes: mood, majoring on depression and anxiety (Zung; 
PHQ; GAD), apathy (PHQ), fatigue (PHQ; BFI) 
7. Frailty (Clinical Frailty Score)  
8. Quality of life assessment (EuroQol 5D) and well-being (Office for National Statistics 
Personal Well-Being) 
9. Vascular measures: Blood pressure, carotid stenosis, vascular stiffness measures 
10. Imaging findings (lesion location, size, pre-stroke changes), DTI, brain and lesion volumes 
11. Inflammation (blood markers) 
12. Genetics 
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Table 3. Cognition categories and operational definitions for R4VaD primary endpoint 
Primary category Operationalisation Sub-category Operationalisation 
Normal cognition 
No evidence of cognitive impairment 
(T-MoCA:20-22          OR               TICSm: 25-39) 
Normal  
Minor 
Neurocognitive 
disorder 
(mild cognitive 
impairment) 
Evidence of cognitive impairment 
(T-MoCA: 15-19           OR                TICSm: 17-24) 
AND 
No evidence of functional impairment 
(mRS <2 OR no change in mRS if pre-stroke mRS >1) 
Single domain 
Scores are reduced by > 1 point in only one 
cognitive domain of T-MoCA or TICSm 
Multi domain 
Scores are reduced by > 1 point in more than 
one cognitive domain of T-MoCA or TICSm 
Dementia 
Clinical diagnosis made independent of study 
Any clinical diagnosis of dementia made by memory 
clinic (or equivalent, this would include primary care) 
 
Any recording of dementia on death certification 
 
Any prescription of cholinesterase inhibitor or 
memantine 
 
OR  
Pre-stroke dementia 
(Baseline assessment IQCODE >3.6 AND MoCA <23) 
 
OR 
In-study evidence of persisting multi-domain cognitive 
impairment 
(T-MoCA score <19 OR TICSm<24 on more than one 
annual follow-up) 
and 
Evidence of functional impairment 
(mRS ≥2 or IQCODE >3.6 at final follow-up) 
Mild 
Cognitive impairments 
(T-MoCA 15-19 OR TICSm 17-23) 
AND 
Minimal functional problems 
(mRS <3) 
Moderate 
More severe cognitive impairments* 
(T-MoCA 10-14 OR TICSm 12-16) 
AND 
More limiting function  
(mRS 3 or 4) AND [Barthel >60 (if available)] 
Severe 
Severest cognitive impairments  
(T-MoCA <10 OR TICSm <12) 
AND  
Most limited function  
Care-home admission 
OR 
(mRS 4,5 OR Barthel <60) 
OR  
Any NPI Q item score of 3  
Death  Death  
Higher scores on cognitive tests indicates better cognitive function. ‘Equivalent’ will include any formal diagnosis of dementia or a dementia subtype made by a suitably 
trained professional, in the UK this is likely to be a geriatrician, neurologist, old age psychiatrist or psychologist. At follow-up, the functional status (mRS and Barthel ADL) 
can be taken from either the participant or the informant, the more severe score should be used to inform the cognitive categorisation. MoCA can be used in place of T-
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MoCA where available. *Possible scenarios that do not fit will be referred for expert panel consensus: eg a) Mild cognitive impairment eg MoCA 15 but more 
severe disability mRS 3 or above which would imply that the disability is driven by physical rather than cognitive problems;  b) More severe cognitive problems but less 
severe disability eg MoCA 14 but mRS 2, which may in many cases represent under scoring of mRS since it seems implausible that a person could have no limitations in 
extended ADL with this level of cognitive impairment  
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Sub-studies 
An aim of R4VaD is to maximise value through addressing additional research questions. Thus, 
in addition to efforts to maximise use of the core data, consent for future studies, etc, several 
sub-studies were included in the original funding application, with the potential to add others.  
Those in the funding application include:   
 
Inflammation: Blood-derived samples are stored for current and future discovery analyses, at 
Manchester University. Planned analyses focuses on a high sensitivity assay of the 
inflammatory cytokine IL-, which is thought to be involved in cognitive decline including PSCI41 
using single molecule counting technology (Singulex) to detect extremely low cytokine levels; 
blood is stored for analysis of other cytokines and proteins.  
Genetics: Genetic susceptibility is important in Alzheimer’s disease (AD) and stroke, and likely 
to be important but under-studied in VaD. Blood is taken for DNA (from all possible 
participants) and transferred to Cambridge University for GWAS, with standard QC, 
imputation and statistical analysis methods to compare genetic profiles with and without 
PSCI. We will estimate genetic heritability for PSCI, and identify SNPs significantly associated 
with dementia at the genome wide significance level of 5 x 10-8. Combining the anticipated 
1000+ highly phenotyped patients from R4VaD with other Consortia will provide ~5,000 
patients with relevant post-stroke outcomes, making a crucial contribution to the global 
cohort.  
Neuroimaging: In centres able to perform MR diffusion tensor imaging (DTI), up to 400 
patients will have DTI and structural sequences (T1-, T2-, Fluid attenuated inversion recovery 
(FLAIR) and susceptibility-weighted (SWI) imaging) to assess several objective DTI tissue 
parameters (fractional anisotropy, mean, axial and radial diffusivity, peak width of 
skeletonised mean diffusivity,42) to test sensitivity for predicting cognitive dysfunction 
compared with visible lesions (infarct size and/or location, WMH, lacunes, perivascular 
spaces, microbleeds, siderosis), brain volume loss or total SVD and frailty scores.43 The MRI 
data are collected centrally to analyse the DTI data and quantify visual features.37 
 
Efforts to minimise bias  
Site training: All sites undergo standard set up procedures to ensure appropriate capabilities, 
resources and recruitment numbers. UK Stroke Research Practitioners are trained in 
screening all patients assessed and diagnosed with stroke, determining the NIHSS, mRS, and 
are commonly experienced in EQ-5D and Barthel scales and cognitive testing. Sites receive 
training in R4VaD recruitment, administering the study questionnaires including cognitive and 
neuropsychiatric tests, completing the CRF, methods to encourage participant retention and 
ensure data completeness, in blood and imaging data acquisition, processing and transfer for 
central storage and analysis. A manual of cognitive testing, responses to frequently asked 
questions and training slides are provided to sites.  
 
Consensus cognition diagnosis: Data from a subsample of those reaching 1 and 2 year follow-
up will be assessed by an expert multidisciplinary panel to assign a definitive diagnosis of 
cognitive status (Table 3) and likely aetiology. 
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Data linkage: We will link unanonymised data to ascertain recurrent stroke, dementia, death, 
place of residence and vital status and limit losses. We will use primary care and secondary 
care records and national registry data to ascertain long term outcomes to supplement 
follow-up information to two years and thereafter.  
 
We will assess external validity of the participants included in the cohort through comparisons 
with the Sentinel Stroke National Audit Program (SSNAP; England, Wales and Northern 
Ireland) and the Scottish Stroke Care Audit (SSCA), and with screening logs at a subset of 
centres, with actions as necessary during recruitment to encourage a representative sample.   
 
Sample size estimates  
We used meta-analyses and trial data to determine sample size and provide scenarios of rates 
of PSCI across different patient characteristics (Table 4).  
 
Table 4: Sample size estimations.  
 
 Stroke severity Total sample 
N 
Outcome at one year after stroke Mild Severe 
 
Dementia (%) 10 20 572 
Dementia (%) 10 15 1914 
Dementia (%) 20 40 236 
Dementia (%) 20 30 825 
Dementia (%) 20 25 3008 
Dementia (%) 20 27 1596 
 
SSNAP provides data on numbers of patients admitted to hospital in England & Wales and 
showed that about 7000 stroke patients are admitted to the applicants’ hospitals/yr with 
about 5700 alive at discharge,44 an additional approximate 1000 (minor strokes) are seen as 
outpatients. The numbers of TIAs are not available for all sites. Thus, recruitment of over 1000 
patients (20%; 125/centre) is feasible in 1yr, and about 2000 in 2yrs (250/centre), i.e. 1600-
1700 ischaemic strokes and about 400 ICHs, with streamlined, light touch approaches. This 
sample would recruit about 20% of patients admitted per applicant centre, and is a 
conservative recruitment estimate for an observational study with very broad entry criteria. 
In addition, it would almost double data on PSCI after ICH. 45 
 
Following considerable interest in the study from CRN-Stroke sites prior to the funding award, 
in addition to seven applicant sites, we expected to include up to 15 other NIHR Clinical 
Research Network Stroke Sites able to recruit in total about 1000 patients per year, thus 
potentially recruiting more than 2000, or completing recruitment of 2000 participants faster 
(Figure 2).   
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     Insert Figure 2 here 
 
We estimated that, at power 0.90, alpha=0.05, we could detect the following differences in 
dementia incidence at one year in mild vs. severe stroke respectively: 20% vs. 27%, n=1596; 
10% vs. 15%, n=1914; 10% vs. 20%, n=572 (Table 4). Thus 2000 patients, with a wide range of 
stroke severities, will allow us to detect small (5% absolute), clinically meaningful differences 
in dementia between mild vs. severe stroke, although the difference in dementia between 
mild and severe is likely to be larger (10+% difference).46 A sample of about 2000 will be able 
to detect differences in degrees of VCI and dementia and by subgroups such as age, pre-
morbid cognitive ability, stroke subtype, or vascular risk factors, in multivariable models. 
 
 
Statistical analyses  
The statistical analysis plan will be published separately.  
 
Study organization and funding  
R4VaD has a Study Steering Committee (SSC) including an independent chair, the applicants, 
funder representatives, an external expert, and user representatives. The SSC meets six 
monthly to review study progress and are consulted ad hoc as necessary. The Study 
Management Group meets monthly by phone or in person. The Substudies Committee 
communicates ad hoc by email and phone to assess proposals. 
In addition to regular email and phone communication between the Study Manager, other 
core study staff and research practitioners of the Clinical Research Network (England, Wales, 
Northern Ireland) and Stroke Research Network (Scotland), a teleconference is held every 4-
6 weeks for all research practitioners at any sites to keep up to date with study procedures 
and share best practice. An R4VaD Newsletter is circulated regularly. 
The Participant Panel communicates by email and teleconference and is consulted on an ad 
hoc basis for matters concerning study design, acceptability or to comment on potential 
research proposals arising from R4VaD.  
An Investigator meeting is held annually in December. 
The work is organised in Work-packages (Study Management including eCRF, Cognition, 
Inflammation, Genetics, Statistical analysis) located between steering committee member 
sites.  
R4VaD is funded by a Priority Programme Award in Vascular Dementia from The Stroke 
Association, British Heart Foundation and Alzheimer’s Society (Grant No. 16 VAD 07), and also 
supported by the Medical Research Council through the Dementia Platform UK.  
 
Data access  
After study completion, data cleaning and lock, anonymised data we will be available for 
secondary uses. Blood, genetic and imaging samples will be accessible for secondary uses. A 
Sub-studies sub-Committee of the R4VaD Study Steering Committee considers proposals for 
substudies.   
 
Impact of SARS-CoV-19  
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The UK started lockdown in March 2020 due to the SARS-CoV-2 (COVID-19) pandemic, the 
Sponsor suspended recruitment on 18th March in line with Government rules and the NIHR 
Urgent Public Health Committee rule to only allow research addressing COVID-19 to continue. 
For participants who had been recruited shortly before the lockdown, we continued early 
follow-up as phone or post (which was already allowed) and all annual follow-ups were 
already by phone/post and continued uninterrupted. However, between January and March 
2020, we had already been detecting impacts of the developing pandemic on participants 
who expressed increasing levels of anxiety and in suicidal thoughts, and serious issues with 
interruptions to social support, particularly from those who had reached the one year follow-
up assessment at that time. Additionally, in view of the associations between cardiovascular 
risk and severe illness in those infected with SARS-CoV-2, we applied for regulatory approvals 
to continue the study to collect data on SARS-CoV-2 exposure, and symptoms, severity and 
treatment received if infected, at presentation with stroke and at annual follow-up in all 
participants. We also modified the data collection procedures accordingly. We submitted the 
applications to the four devolved UK administrations (Ethics and Research and Development 
Offices), and the NIHR Urgent Public Health Committee, on 3rd April 2020. Approval was 
granted in Scotland and England on 6th and 22nd April respectively, and the study restarted 
recruitment, during the pandemic lockdown, in Scotland on 17th April and in England on 6th 
May in the (so far) 11 sites where resource availability made it feasible to do so. Since 
lockdown was eased in the UK in early July 2020, all other sites are gradually opening.   
 
Discussion 
R4VaD is a prospective observational, longitudinal inception cohort with central follow-up 
being carried out in major UK stroke centres representing geographic and socioeconomic 
diversity. Recruitment started on September 25th 2018 in Edinburgh; by March 13th 2020, 
1271 participants had been recruited across 53 sites (Figure 2). The mean age is 69.8 years 
(SD13.3), recruited at median 7.0 (IQR 3.0-17.0) days post-stroke, most have ischaemic stroke 
(83%), 7% lack capacity; and 42% have an informant. Recruitment will continue for two years 
or until at least 2000 patients have been recruited. Note that on March 18th 2020, the study 
temporarily suspended recruitment due to Government restrictions from the SARS-CoV-2 
pandemic, but re-opened to recruitment in April 2020, as detailed above, and has now 
recruited 1416 participants, i.e. 142 during the pandemic lockdown in the 11/53 centres that 
had resource available to continue. We will continue hereon collecting details on SARS-CoV-
2 on all participants, including those recruited prior to the pandemic, enabling a before, 
during and after the pandemic analysis. While the pandemic has affected stroke services and 
research in all countries affected by SARS-CoV-2, and has undoubtedly delayed recruitment 
to R4VaD, we hope that the additional information gained by collecting data on SARS-CoV-2 
across the UK will provide valuable additional information in the early and late impacts of the 
measures taken in the UK to address the pandemic and the infection itself on a vulnerable 
and high risk group of patients. 
 
Fundamental gaps in knowledge on stroke, cognition and dementia were highlighted 
recently.1, 15  Dementia varies from 7% (population studies, 1st stroke, no pre-stroke 
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dementia) to 41% (hospital studies with recurrent stroke and pre-stroke dementia) at one 
year,2 but with confidence intervals spanning 2-3 fold differences in dementia that are largely 
unexplained. Prevalence of MCI (29-68%) and dementia (8-22%) after TIA are variable and 
based on few patients.47 The aetiology, risk factors and prognosis of PSCI are poorly 
understood. They lack information on stroke subtype, e.g. lacunar stroke, or ICH,45 
progression of VCI to  dementia,15 or PSCI rates beyond the first year after stroke.2, 48  Few 
studies consider pre-morbid intelligence49 or failing cognition pre-stroke,3 yet both factors 
affect risk of stroke and of PSCI. While the APOE-4 genotype is a major risk factor for AD with 
an allelic frequency of 15% in whites, in patients with TIA or stroke only APOE-4 
homozygosity was associated with increased risk of dementia post-stroke yet was present in 
less than 2% of patients.50 Cerebral amyloid angiopathy (CAA), a vascular disease which 
causes stroke and dementia, apparently is also not associated with the APOE-4 genotype, 
even in patients with severe CAA.51 R4VaD should progress understanding of different 
contributors to cognitive impairment in the presence of cerebrovascular disease.   
 
The limited data on the complex interplay between individual risk factors and PSCI or 
dementia, how risk factors affect dementia pathophysiology, or brain health and resilience,52 
make it difficult to advise individuals, plan randomised clinical trials or develop clinical 
services. Generalisability of data is restricted by selection bias, suboptimal testing and 
attrition.4 Cognitive testing is recommended in UK stroke guidelines,53 but many tests are 
impractical for stroke or insensitive to VCI.4, 15 Lack of proven clinical utility may explain why 
many GPs do not perform cognitive screens routinely. Use of different cognitive tests inflates 
variance in VCI/dementia rates, hampers between-study comparisons and efforts to 
understand mechanisms, as individual studies lacked vascular risk factor adjustment; 
similarly, systematic reviews2 and routine health data54 disagree on the importance of 
common risk factors. Cognitive testing alone does not capture the psychological sequelae of 
stroke:  fatigue, apathy, mood16 affect cognition; in turn, 3-month cognition scores correlate 
highly with dependency, mood, and quality of life.46 
 
A broad stroke cohort in R4VaD will capture all potential VaD phenotypes (small vessel 
disease, multi-infarct, strategic infarct, mixed pathologies),4 strengthening knowledge on 
VaD. We will collect cognitive information across a continuum of stroke severities because 
cognition is relevant after all severities of stroke.2 The prospects for physical recovery, even 
after severe stroke, are changing radically with thrombolysis, thrombectomy, improved 
discharge support and community rehabilitation, but with unknown  impact on cognition. 
Improved physical recovery from initially severe stroke may unmask potentially limiting 
cognitive deficits and equally, deficits in mild stroke may be missed by conventional clinical 
services yet restrict independence.48  
 
R4VaD, designed to address these highlighted issues, will assess long term cognition after 
stroke in a broad, inclusive population, along with providing valuable information on 
mechanisms and risk factors. The achievement of recruitment targets and completeness of 
baseline and follow-up data, will give practical evidence of the acceptability, feasibility and 
practicality of the assessments ‘in the field’. We acknowledge the mortality and attrition 
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associated with trying to include all severities of stroke, so have included multimodal patient-
focussed follow-up to minimise losses, and analysis methods to account for competing risk 
biases associated with early mortality.  
 
R4VaD will provide well-phenotyped patients (including cortical and subcortical VaD/VCI), 
stratified and consented for re-contact for future trials, which is particularly important given 
the recent difficulties in recruiting patients with VCI into trials. Furthermore, patients with 
stroke represent an ‘enriched’ sample, similar to the relationship between MCI and AD.  
R4VaD embeds priority substudies on inflammation and genetics, and we store blood samples 
for future discovery. R4VaD will help validate the proposed staged approach to cognition and 
related assessments, for research and clinical use.  R4VaD will provide data to inform service 
design and assist those at risk of PSCI to plan their future.5 R4VaD combines the UK’s 
considerable stroke research strengths, which have helped transform stroke care into co-
ordinated prevention, treatment and recovery in the last 25 years, with the dementia 
research expertise of the DP-UK and Dementia Research Network.52 Although stroke and 
dementia services and Research Networks currently operate in completely different ways 
(different hospitals, time frames, scheduling, patient caseload) we hope that R4VaD will 
encourage clinical services and research sites for dementia and stroke to operate more closely 
together since the two disorders’ risk factor profiles and impacts on daily life are so closely 
intertwined. 
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Figure 1: Flow chart of recruitment and study protocol 
 
 
Figure 2. Recruitment actual versus target as at 20 March 2020 
 
 
 
 
 
